A EFFACER
Trials Results

  • Group by...

TrialStudied treatmentControl treatmentpatientsROBResultNCT

melanoma

Interferon alpha
EORTC18871/DKG 80-1 (Kleeberg), 2004rIFN alpha-2bobservationadjuvantNegative
EORTC18952 (Eggermont), 2005ID IFN alpha-2b (I M)observationadjuvantNegative
EORTC18991 (Eggermont), 2008PEG IFN alpha-2b (I M)observationadjuvantSuggesting
Nordic IFN Trial, 2011ID IFN alpha-2b (I M)observationadjuvantSuggesting
ipilimumab
EORTC 18071 (Eggermont), 2015ipilimumabplaceboadjuvant Low risk of bias Conclusive NCT00636168
nivolumab
CheckMate 238, 2017nivolumabipilimumabadjuvant Low risk of bias ConclusiveNCT02388906
pembrolizumab
KEYNOTE-054, 2018pembrolizumabplaceboadjuvant Low risk of bias Conclusive NCT02362594
trametinib + dabrafenib
COMBI-AD, 2017trametinib and dabrafenibplaceboadjuvantSuggestingNCT01682083
COMBI neo, 2018trametinib and dabrafenib SOCadjuvant - NCT02231775
vemurafenib
BRIM 8, 2018vemurafenibplaceboadjuvantSuggestingNCT01667419



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons